BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26874199)

  • 1. Sestrin-2 is significantly increased in malignant pleural effusions due to lung cancer and is potentially secreted by pleural mesothelial cells.
    Tsilioni I; Filippidis AS; Kerenidi T; Budanov AV; Zarogiannis SG; Gourgoulianis KI
    Clin Biochem; 2016 Jun; 49(9):726-728. PubMed ID: 26874199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
    Zennaro L; Vanzani P; Nicolè L; Cappellesso R; Fassina A
    Cancer Cytopathol; 2017 May; 125(5):341-348. PubMed ID: 28140518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleural effusion levels of DJ-1 are increased in elderly lung cancer patients with malignant pleural effusions.
    Vavougios G; Kerenidi T; Tsilioni I; Zarogiannis SG; Gourgoulianis KI
    Redox Rep; 2015; 20(6):254-8. PubMed ID: 26125099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
    Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
    Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters.
    Bayram N; Karakan Y; Uyar M; Ozyurt B; Filiz A
    Niger J Clin Pract; 2018 Jan; 21(1):59-62. PubMed ID: 29411725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiopoietin-2 levels are elevated in exudative pleural effusions.
    Kalomenidis I; Kollintza A; Sigala I; Papapetropoulos A; Papiris S; Light RW; Roussos C
    Chest; 2006 May; 129(5):1259-66. PubMed ID: 16685017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
    Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
    Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
    Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
    Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of vascular endothelial growth factor (VEGF) in neoplastic and tuberculosis effusions--preliminary results].
    Jankowska R; Porebska I; Dyła T
    Pneumonol Alergol Pol; 2002; 70(5-6):258-64. PubMed ID: 12518624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Elevated pleural copeptin levels can distinguish to exudate from transudates].
    Gümüş A; Çınarka H; Karataş M; Kırbaş A; Kayhan S; Şahin Ü
    Tuberk Toraks; 2014; 62(4):267-72. PubMed ID: 25581690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).
    Verma A; Abisheganaden J; Light RW
    Lung; 2016 Feb; 194(1):147-53. PubMed ID: 26678281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vascular endothelial growth factor in benign and malignant pleural effusions].
    Kaya A; Poyraz B; Celik G; Ciledag A; Gulbay BE; Savas H; Savas I
    Arch Bronconeumol; 2005 Jul; 41(7):376-9. PubMed ID: 16029730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions.
    Korczyński P; Mierzejewski M; Krenke R; Safianowska A; Light RW
    Pol Arch Intern Med; 2018 Jun; 128(6):354-361. PubMed ID: 29968696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts.
    Yang Q; Niu Y; Wen JX; Yang DN; Han YL; Wen XH; Yan L; Huang JH; Chen H; Zheng WQ; Jiang TW; Hu ZD
    Ther Adv Respir Dis; 2023; 17():17534666231216566. PubMed ID: 38084849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of pleural fluid data in patients with malignant effusion.
    Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
    Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
    Fiorelli A; Vicidomini G; Di Domenico M; Napolitano F; Messina G; Morgillo F; Ciardiello F; Santini M
    Interact Cardiovasc Thorac Surg; 2011 Mar; 12(3):420-4. PubMed ID: 21172937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
    Thomas R; Cheah HM; Creaney J; Turlach BA; Lee YC
    Chest; 2016 Jun; 149(6):1494-500. PubMed ID: 26836920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions.
    Economidou F; Antoniou KM; Tzanakis N; Sfiridaki K; Siafakas NM; Schiza SE
    Respir Med; 2008 May; 102(5):774-9. PubMed ID: 18304793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.
    Ozsu S; Oztuna F; Mentese A; Abul Y; Ozlu T
    Clin Respir J; 2016 Jan; 10(1):61-6. PubMed ID: 25043397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.